Remedy for glaucoma comprising Rho kinase inhibitor and...

Details Remedy for glaucoma comprising Rho kinase inhibitor and... Remedy for glaucoma comprising Rho kinase inhibitor and...

2011-07-05

2011-07-05

Padmanabhan, Sreeni (Department: 1617)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

C514S236200, C514S300000, C514S913000

Reexamination Certificate

active

07972612

ABSTRACT:
A subject of the present invention is to find utility of a combination of a Rho kinase inhibitor having a novel action and a β-blocker as a therapeutic agent for glaucoma. Actions of reducing intraocular pressure are complemented and/or enhanced each other by combining the Rho kinase inhibitor with the β-blocker. For the administration mode, each drug can be administered in combination or in mixture.

REFERENCES:
patent: 4952581 (1990-08-01), Bito et al.
patent: 5502052 (1996-03-01), DeSantis
patent: 6187304 (2001-02-01), Jin et al.
patent: 6271224 (2001-08-01), Kapin et al.
patent: 6673812 (2004-01-01), Azuma et al.
patent: 2005/0014783 (2005-01-01), Dole et al.
patent: 2005/0043412 (2005-02-01), Ichikawa et al.
patent: 2005/0245509 (2005-11-01), Nakajima et al.
patent: 286903 (1988-10-01), None
patent: 308135 (1989-03-01), None
patent: 639563 (1995-02-01), None
patent: 0 757 038 (1997-02-01), None
patent: 0 253 717 (1998-01-01), None
patent: 956865 (1999-11-01), None
patent: 1034793 (2000-09-01), None
patent: 7-508030 (1995-09-01), None
patent: 2726672 (1997-12-01), None
patent: 2001-509780 (2001-07-01), None
patent: 63-79828 (2002-05-01), None
patent: 2003-292442 (2003-10-01), None
patent: 2004-513148 (2004-04-01), None
patent: WO 90/02553 (1990-03-01), None
patent: WO 93/16701 (1993-09-01), None
patent: WO 93/23082 (1993-11-01), None
patent: WO 94/06433 (1994-03-01), None
patent: 95/28387 (1995-10-01), None
patent: WO 97/23222 (1997-07-01), None
patent: WO 98/06433 (1998-02-01), None
patent: WO 00/09162 (2000-02-01), None
patent: WO 00/25771 (2000-05-01), None
patent: WO 00/57914 (2000-10-01), None
patent: 02/38158 (2002-05-01), None
patent: WO 02/38158 (2002-05-01), None
patent: WO 03/049745 (2003-06-01), None
Konstas et al., The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients, Jun. 1999, Eye,13 (Pt3a), printed from http://www.ncbi.nlm.nih.gov/pubmed/10624424 on May 12, 2009, Abstract only, 2 pages.
Abate M.A. et al., “Effect of Naproxen and Sulindac on Blood Pressure Response to Atenolol,”DICP—Annals. of Pharmacotherapy, vol. 24, No. 9, 1990, pp. 810-813.
Zhou Yan et al., “Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aβ42by Inhibiting Rho,”Science, vol. 302, No. 5648, Nov. 14, 2003, pp. 1215-1217.
Honjo et al., “Effects of Protein Kinase Inhibitor, HA1077, on Intraocylar Pressure and Outflow Facility in Rabbit Eyes,”Archived of Ophthalmology, vol. 119, No. 8, Aug. 2001, pp. 1171-1178.
Database WPI Week 200060, Derwent Publications ltd., London, GB; AN 2000-628321 of WO 00/57914 (Santen Pharmaceutical Co., Ltd.; Oct. 5, 2002).
Clark A.F. et al., “Advances in Glaucoma Therapeutics,”Expert Opinion of Emerging Drugs, 2002, United Kingdom, vol. 7, No. 1, May 2002, pp. 141-163.
Uehara, M. et al., “Calcium Sensitization of Smooth Muscle Mediated by a Rho-Associated Protein Kinase in Hypertension,”Nature, (1997), 389, pp. 990 to 994.
Mariko Asahi et al., “Ryokunaisho to Ryokunaisho Chiryo Yakuzai (Fukuyaki Shido Manual II, Dai 10 Kai),”The Pharmaceuticals Monthly, (1996), 38(9), pp. 2311 to 2331.
Kuniteru Shirato, “I. Ryokunaisho no Yakubutsu Ryoho 1. Gairon” (Chiryoyaku no Sentaku o Dou Kangaerunoka), (“Some Practical Aspect in Medical Therapy”) Ganka, (2002), 44(11), pp. 1443 to 1448.
Tatsuro Fukuchi, “I. Ryokunaisho no Yakubutsu Ryoho 2. Ryokunaisho Chiryoyaku C. Kokan Shinkei Sogaiyaku β Shadanyaku,” (“β-Adrenergic Antagonists”) Ganka, (2002), 44(11), pp. 1458 to 1463.
Ikuo Azuma et al., “Effects of Bunazosin Hydrochloride Ophthalmic Solution in Combination with Timolol Maleate Ophthalmic Solution in Patients with Open-Angle Glaucoma and Ocular Hypertension-Comparison with Dipivefrin Hydrochloride Ophthalmic Solution,”The Journal of the Eye, (2002), 19(2), pp. 261 to 266.
Yuichiro Otake et al., “Effect and Safety of Combined Therapy with Betaxolol and isopropyl Unoprostone,”The Journal of the Eye, (2000), 17(5), pp. 687 to 690.
Hideki Tokushige, “ROCK Sogaiyaku to Ryokunaisho” (“ROCK Inhibitor and Glaucoma”),Bio Clinica, (2002), 17(13), pp. 1191 to 1194.
Hoyng, P.F.J. et al., “Pharmacological Therapy for Glaucoma,”Drugs, (2000), 59(3), pp. 411 to 434.
Megumi Honjo et al., “Effects of Rho-Associated Protein Kinase Inhibitor Y-27632 on Intraocular Pressure and Outflow Facility,”Invest. Ophthalmol.&Vis. Sci., vol. 42, No. 1 (2001). pp. 137-144.
P. Vasantha Rao et al., “Modulation of Aqueous Humor Outflow Facility by the Rho Kinase-Specific Inhibitor Y-27632,”Invest. Ophthalmol.&Vis. Sci., vol. 42, No. 5. (2001), pp. 1029-1037.
“Gekkan Ganka Shinryo Practice (Practical Ophthalmology),” 42, Tenganyaku no Tsukaikata (How to Use Eye Drops), 1999, pp. 52-53.
“Gekkan Yakuji (The Pharmaceuticals Monthly),” 1996, vol. 38, No. 9, pp. 2311-2331.
Hiromitsu Nagumo et al., “Rho Kinase Inhibitor HA-1077 Prevents Rho-Mediated Myosin Phosphatase Inhibition in Smooth Muscle Cells,”Am. J. Physiol., 278, C57-C65, (2000).
Demand for Trial dated Dec. 3, 2009 in the Trial for Invalidation for Japanese Patent 4,314,433.
Notice of Grounds of Rejection dated Aug. 27, 2007 in the Trial for Invalidation for Japanese Patent 4,314,433.
Board Decision in the Trial for Invalidation for Japanese Patent 4,314,433 translation dated Nov. 22, 2010.
Kyle A. Parrow et al., “Is It Worthwhile to Add Dipivefrin HC1 0.1% to Topical β1˜, β2˜blocker Therapy?”,Ophthalmology, 96(9), 1338-1342 (1989.
Mark B. Abelson et al., “Sustained Reduction of Intraocular Pressure in Humans With the Calcium Channel Blocker Verapamil,”American Journal of Ophthalmology, 105(2), 155-159 (1988).
Kristine A. Erickson et al., “Verapamil Increases Outflow Facility in the Human Eye,”Exp. Eye Res.61(5), 565-567 (1995).
Jing-Ming Dong et al., “cAMP-induced Morphological Changes Are Counteracted by the Activated RhoA Small GT Pase and the Rho Kinase ROKα*,”J. Bio. Chem., 273, No. 35, 22554-2:2562 (1998).
Roser Busca et al “Inhibition of Rho Is Required for cAMP-induced Melanoma Cell Differentiation,”Mol. Biol. Cell., 9(6), 1367-1378 (1998).
Michael Diestelhorst, “Combined therapy of Pilocarpine or Latanoprost with Timolol Versus Latanoprost Monotherapy,”Surv. Ophthalmology, 47, Suppl 1. S155-S161 (2002).
Philip P. Ellis et al., “Aqueous Humor Pilocarpine and Timolol Levels After Instillation of the Single Drug or in Combination,”Invest. Ophthalmology&Visual Science, 32(3), 520-522 (1991).
Asahi Kasei Press Release of Aug. 20, 2002.
Calbiochem General Catalog, 2002-2003.
WAKO Bio Window, 38 Mar. 2002.
“Ryokunaisho to Ganatsu (Glaucoma and Intraocular Pressure),”Ganka(Ophthalmology), No. 37.

Affiliated with

Also associated with

Rating

Remedy for glaucoma comprising Rho kinase inhibitor and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Remedy for glaucoma comprising Rho kinase inhibitor and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Remedy for glaucoma comprising Rho kinase inhibitor and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2638418